Advertisement

Azapropazone pp 175-184 | Cite as

Azapropazone in gout and hyperuricaemia

  • G. Nuki
  • F. Grinlinton
  • J. Palit
  • R. Wallace

Abstract

After 20 years of clinical use as a non-steroidal anti-inflammatory drug (NSAID) azapropazone is now well established as both a useful agent for treating attacks of acute gouty arthritis and as single agent interval therapy for the management of patients with hyperuricaemia and recurrent gouty arthritis where uric acid lowering drug therapy is indicated

Keywords

Xanthine Oxidase Serum Urate Gouty Arthritis Acute Gout Uric Acid Excretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frank, K.O. (1971). Investigation of the uricosuric action of azapropazone. Z. Rheumaforsch., 30, 368–373Google Scholar
  2. 2.
    Thomas, A.L., Majoos, F.L. and Nuki, G. (1983). Preliminary studies with azapropazone in gout and hyperuricaemia. Eur. J. Rheumatol. Inflamm., 6, 149–154PubMedGoogle Scholar
  3. 3.
    Herne, N., Hugny, D., Hauteville, D., Desbaumes, J., De Muizon, H. and Andran, M. (1977). L’azapropazone, Etude de son activite hypouricemiante. Nouv. Presse. Med., 6, 1657–1658Google Scholar
  4. 4.
    Dieppe, P.A., Doherty, M., Whicher, J.T. and Walters, G. (1977). The treatment of gout with azapropazone: clinical and experimental studies. Eur. J. Rheumatol. Inflamm., 4, 392–400Google Scholar
  5. 5.
    Higgen, C.S. and Scott, J.T. (1984). The uricosuric action of azapropazone: dose response and comparison with probencid. Br. J. Clin. Pharmacol, 18, 439–443Google Scholar
  6. 6.
    Steele, T.H. (1973). Urate secretion in man: the pyrazinamide suppression test. Ann. Intern. Med., 79, 734–737PubMedGoogle Scholar
  7. 7.
    Kippin, I., Whitehouse, M.W. and Klinenberg, J.R. (1974). Pharmacology of uricosuric drugs. Ann. Rheum. Dis., 33, 391–393CrossRefGoogle Scholar
  8. 8.
    Postelethwaite, A.E., Gutman, R.A. and Kelley, W.N. (1974). Salicylate mediated increase in uric acid removal during haemodialysis: evidence for urate binding in vivo. Metabolism, 23, 771–777CrossRefGoogle Scholar
  9. 9.
    Jahn, U. and Thiele, K. (1988). In-vitro inhibition of xanthine oxidase by azapropazone and 8-hydroxy azapropazone. Arzneim. Forsch., 38, 507–508Google Scholar
  10. 10.
    Gibson, T., Simmonds, H.A., Armstrong, R.D., Fairbanks, L.D. and Rogers, A.V. (1984). Azapropazone — a treatment of hyperuricaemia and gout? Br. J. Rheumatol., 23, 44–51PubMedCrossRefGoogle Scholar
  11. 11.
    Rylance, HJ., Wallace, R.C. and Nuki, G. (1983). Analysis of human plasma and urine purines using high performance liquid chromatograghy. Ann. Rheum. Dis., 42, (Suppl), 85CrossRefGoogle Scholar
  12. 12.
    Sorenson, C.B. (1965). Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum., 8, 694–703CrossRefGoogle Scholar
  13. 13.
    Frank, O. (1976). The treatment of acute gouty arthritis. J. Clin. Chem. Clin. Biochem., 14, 290Google Scholar
  14. 14.
    Dunky, A., Bartsch, G. and Eberl, R. (1984). The intravenous application of azapropazone in the treatment of acute gout. Arthritis Rheum., 6, 1–6Google Scholar
  15. 15.
    Thompson, M., Sanders, P.A., Walker, D.J. and Templeton, J.S. (1985). Abst. XVIth International Congress Rheumatology, SydneyGoogle Scholar
  16. 16.
    Brune, K, Rainsford, K.D., Wagner, K. and Peskar, B.A. (1981). Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn Schmiedeberg’s Arch. Pharmacol., 315, 269–281CrossRefGoogle Scholar
  17. 17.
    Lewis, D.A., Capstick, R.B. and Ancill, R.J. (1971). The action of azapropazone, oxyphenbutazone and phenylbutazone on lysosomes. J. Pharm. Pharmacol., 23, 931PubMedCrossRefGoogle Scholar
  18. 18.
    Mackin, W.M., Rakich, S.M. and Marshall, C.L. (1986). Inhibition of rat neutrophil functional responses by azapropazone, an anti-gout drug. Biochem. Pharmacol, 35, 917–922PubMedCrossRefGoogle Scholar
  19. 19.
    Palit, J., Nuki, G. (Unpublished observations)Google Scholar
  20. 20.
    Bell, A.L, Hurst, N.P, French, J.K., Adamson, J. and Nuki, G. (1987). Effects of non-steroidal anti-inflammatory drugs and antimalarial agents on blood monocyte superoxide anion production in vitro and ex vivo in rheumatoid arthritis. In: A.J.G. Swaark and J.K. Forster, (eds.) Free Radicals and Arthritis Diseases., Topics in Ageing Research in Europe. 11, 151–160Google Scholar
  21. 21.
    Thomas, A. and Nuki, G. (1979). The hypouricaemic effects of azapropazone and phenylbutazone. XIXth European Congress Rheumatology, WiesbadenGoogle Scholar
  22. 22.
    Templeton, J.S. (1983). Longterm comparison of azapropazone with allopurinol in control of chronic gout and hyperuricaemia. Ann. Rheum. Dis., 42 (Suppl. 1), 92–93CrossRefGoogle Scholar
  23. 23.
    Fraser, R.C, Harvard-Davis, R. and Walker, F.S. (1987). Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J. Roy. Coll. Gen. Practit., 37, 409–411Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • G. Nuki
  • F. Grinlinton
  • J. Palit
  • R. Wallace

There are no affiliations available

Personalised recommendations